Matthew R. Farren

1.8k citations

34 papers · 1.3k indexed · h-index 19

Oncology top 5%
- Pancreatic and Hepatic Oncology Research 5
- Cancer Immunotherapy and Biomarkers 5
- Cytokine Signaling Pathways and Interactions 5
Immunology top 5%
- Immunotherapy and Immune Responses 4
- Phagocytosis and Immune Regulation 4
- Immune cells in cancer 4
Cancer Research top 10%
Biotechnology top 10%
Behavioral Neuroscience
Molecular Biology
- Nuclear Structure and Function 3
Surgery
- Cholangiocarcinoma and Gallbladder Cancer Studies 3

Co-authors: Kelvin P. Lee Gregory B. Lesinski Colleen S. Netherby Scott I. Abrams Thomas A. Mace Kebin Liu Qiang Hu Paul N. Bogner
Cited by: Oncology Immunology Cancer Research
Journals: Journal of Clinical Investigation (1 paper)Blood (2 papers)The Journal of Immunology (1 paper)
Partner nations: United States United Kingdom Austria

In The Last Decade

Matthew R. Farren

32 papers receiving 1.3k citations

Peers

Countries citing papers authored by Matthew R. Farren

Since Specialization

Citations

This map shows the geographic impact of Matthew R. Farren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew R. Farren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew R. Farren more than expected).

Fields of papers citing papers by Matthew R. Farren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew R. Farren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew R. Farren. The network helps show where Matthew R. Farren may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Matthew R. Farren, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Matthew R. Farren Line = papers co-authored together Matthew R. Farren links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The FGFR inhibitor pemigatinib overcomes cancer drug resistance to KRAS G12C inhibitors in mesenchymal lung cancer PLoS ONE ·Angela Abdollahi,Margaret Favata,Michaël Weber,Valerie Roman,Rodrigo Hess,K. D. Hammond,Matthew R. Farren,Mike Schaffer,Aidan G. Gilmartin,Hui Wang,Jonathan Rios‐Doria,Alejandro Amador‐Arjona	2025	0
2	A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186 Cancer Immunology Immunotherapy ·Cameron J. Herting,Matthew R. Farren,Yan Tong,Ziyue Liu,Bert H. O’Neil,Tanios Bekaii‐Saab,Anne M. Noonan,Christopher McQuinn,Thomas A. Mace,Walid L. Shaib,Christina Wu,Bassel F. El‐Rayes,Safi Shahda,Gregory B. Lesinski	2021	23
3	Heat Shock Protein-90 Inhibition Alters Activation of Pancreatic Stellate Cells and Enhances the Efficacy of PD-1 Blockade in Pancreatic Cancer Molecular Cancer Therapeutics ·Yuchen Zhang,Michael B. Ware,Mohammad Y. Zaidi,Amanda N. Ruggieri,Brian M. Olson,Hannah Komar,Matthew R. Farren,Ganji Purnachandra Nagaraju,Chao Zhang,Zhengjia Chen,Juan M. Sarmiento,Rafi Ahmed,Shishir K. Maithel,Bassel F. El‐Rayes,Gregory B. Lesinski	2020	39
4	Suppressive myeloid cells are expanded by biliary tract cancer-derived cytokines in vitro and associate with aggressive disease British Journal of Cancer ·Michael B. Ware,Mohammad Y. Zaidi,Jennifer Yang,Michael K. Turgeon,Alyssa M. Krasinskas,Thomas A. Mace,Kaitlin Keenan,Matthew R. Farren,Amanda N. Ruggieri,Yiman Li,Chao Zhang,Zhengjia Chen,Gregory Young,Omar Elnaggar,Zheng Che,Shishir K. Maithel,Tanios Bekaii‐Saab,Bassel F. El‐Rayes,Gregory B. Lesinski	2020	5
5	Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy JCI Insight ·Matthew R. Farren,Layal Sayegh,Michael B. Ware,Hsiao-Rong Chen,Jingjing Gong,Yan Liang,Alyssa M. Krasinskas,Shishir K. Maithel,Mohammad Y. Zaidi,Juan M. Sarmiento,David A. Kooby,Pretesh Patel,Bassel F. El‐Rayes,Walid L. Shaib,Gregory B. Lesinski	2019	41
6	Soy isoflavones and their metabolites modulate cytokine-induced natural killer cell function Scientific Reports ·Thomas A. Mace,Michael B. Ware,Samantha A. King,Shannon Loftus,Matthew R. Farren,Elizabeth L. McMichael,Steven D. Scoville,Connor M. Geraghty,Gregory Young,William E. Carson,Steven K. Clinton,Gregory B. Lesinski	2019	54
7	The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors Molecular Cancer Therapeutics ·Matthew R. Farren,Rebecca C. Hennessey,Reena Shakya,Omar Elnaggar,Gregory Young,Kari Kendra,Yosef Landesman,Sivan Elloul,Marsha Crochiere,Boris Klebanov,Trinayan Kashyap,Christin E. Burd,Gregory B. Lesinski	2017	23
8	Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment Cancer Research ·Sobeyda B. Gomez-Chou,Agnieszka Świdnicka‐Siergiejko,Niharika Badi,Myrriah Chavez-Tomar,Gregory B. Lesinski,Tanios Bekaii‐Saab,Matthew R. Farren,Thomas A. Mace,Carl Schmidt,Yan Liu,Defeng Deng,Rosa F. Hwang,Liran Zhou,Todd T. Moore,Deyali Chatterjee,Huamin Wang,Xiaohong Leng,Ralph B. Arlinghaus,Craig D. Logsdon,Zobeida Cruz‐Monserrate	2017	114
9	Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities Molecular Cancer Therapeutics ·Erin E. Talbert,Jennifer Yang,Thomas A. Mace,Matthew R. Farren,Alton B. Farris,Gregory Young,Omar Elnaggar,Zheng Che,Cynthia Timmers,Priyani Rajasekera,Jennifer M. Maskarinec,Mark Bloomston,Tanios Bekaii‐Saab,Denis C. Guttridge,Gregory B. Lesinski	2016	29
10	Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma Molecular Therapy ·Anne M. Noonan,Matthew R. Farren,Susan Geyer,Ying Huang,Sanaa Tahiri,Daniel H. Ahn,Sameh Mikhail,Kristen K. Ciombor,Shubham Pant,Santiago Aparo,Jennifer Sexton,John L. Marshall,Thomas A. Mace,Christina Wu,Bassel F. El‐Rayes,Cynthia Timmers,James A. Zwiebel,Gregory B. Lesinski,Miguel A. Villalona‐Calero,Tanios Bekaii‐Saab	2016	119
11	Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer Clinical Cancer Research ·Matthew R. Farren,Thomas A. Mace,Susan Geyer,Sameh Mikhail,Christina Wu,Kristen K. Ciombor,Sanaa Tahiri,Daniel H. Ahn,Anne M. Noonan,Miguel A. Villalona‐Calero,Tanios Bekaii‐Saab,Gregory B. Lesinski	2015	69
12	Leptin, BMI, and a Metabolic Gene Expression Signature Associated with Clinical Outcome to VEGF Inhibition in Colorectal Cancer Cell Metabolism ·Aurélien Pommier,Matthew R. Farren,Bhavika Patel,Mark Wappett,Filippos Michopoulos,Neil R. Smith,Jane Kendrew,Jeremy Frith,R. Huby,Catherine A. Eberlein,Hayley Campbell,Christopher J. Womack,Paul Smith,Jane Robertson,Shethah Morgan,Susan E. Critchlow,Simon T. Barry	2015	15
13	Stressful Presentations: Mild Cold Stress in Laboratory Mice Influences Phenotype of Dendritic Cells in Naïve and Tumor-Bearing Mice Frontiers in Immunology ·Kathleen M. Kokolus,Haley Spangler,Benjamin Povinelli,Matthew R. Farren,Kelvin P. Lee,Elizabeth A. Repasky	2014	53
14	E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin αvβ6 and maintained through TGFβ signalling Oncogene ·Catherine A. Eberlein,Claire Rooney,Sarah J. Ross,Matthew R. Farren,Hazel M. Weir,Simon T. Barry	2014	42
15	Tumor Stromal Architecture Can Define the Intrinsic Tumor Response to VEGF-Targeted Therapy Clinical Cancer Research ·Neil R. Smith,Dawn Baker,Matthew R. Farren,Aurélien Pommier,Ruth Swann,Xin Wang,Sunita Mistry,Karen McDaid,Jane Kendrew,Chris Womack,Stephen R. Wedge,Simon T. Barry	2013	111
16	Autocrine GM-CSF transcription in the leukemic progenitor cell line KG1a is mediated by the transcription factor ETS1 and is negatively regulated through SECTM1 mediated ligation of CD7 Biochimica et Biophysica Acta (BBA) - General Subjects ·Christina Bade‐Doeding,Wiebke Göttmann,Anja Baigger,Matthew R. Farren,Kelvin P. Lee,Rainer Blasczyk,Trevor Huyton	2013	5
17	RNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor Cediranib PLoS ONE ·James Bradford,Matthew R. Farren,Steve Powell,Sarah Runswick,Susie Weston,Helen Brown,Oona Delpuech,Mark Wappett,Neil R. Smith,T. Hedley Carr,Jonathan R. Dry,Neil Gibson,Simon T. Barry	2013	24
18	Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis Journal of Clinical Investigation ·Jeremy D. Waight,Colleen S. Netherby,Mary L. Hensen,Austin Miller,Qiang Hu,Song Liu,Paul N. Bogner,Matthew R. Farren,Kelvin P. Lee,Kebin Liu,Scott I. Abrams	2013	263
19	Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologies Angiogenesis ·Matthew R. Farren,Susie Weston,Helen Brown,Nicola Broadbent,Steve Powell,Robert A. Shaw,Neil R. Smith,Rachael Inglis,Alex Graham,Sue Ashton,Stephen R. Wedge,Simon T. Barry	2012	6
20	Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression Immunologic Research ·Matthew R. Farren,Louise Carlson,Kelvin P. Lee	2009	22

About Matthew R. Farren

Matthew R. Farren is a scholar working on Immunology, Oncology and Cancer Research, having authored 34 papers that have together received 1.3k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (5 papers), Cancer Immunotherapy and Biomarkers (5 papers), Cytokine Signaling Pathways and Interactions (5 papers), Immunotherapy and Immune Responses (4 papers), Phagocytosis and Immune Regulation (4 papers), Immune cells in cancer (4 papers), Nuclear Structure and Function (3 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers). The work is most often cited by research in Oncology (625 citations), Immunology (482 citations) and Cancer Research (195 citations). Matthew R. Farren has collaborated with scholars based in United States, United Kingdom and Austria. Frequent co-authors include Kelvin P. Lee, Gregory B. Lesinski, Colleen S. Netherby, Scott I. Abrams, Thomas A. Mace, Kebin Liu, Qiang Hu, Paul N. Bogner, Song Liu and Austin Miller. Their work appears in journals such as Journal of Clinical Investigation, Blood and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact